Viatris (HAM:VIA) Long-Term Debt: €10,738 Mil (As of Mar. 2026)


HAM:VIA Viatris Inc HAM:VIA
60 GF Score
Price €14.12
GF Value €9.57
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Long-Term Debt?

Viatris HAM:VIA -4.10% 60 Long-Term Debt is €10,738 Mil as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.57 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Viatris's Long-Term Debt for the quarter that ended in Mar. 2026 was €10,738 Mil.

Viatris's quarterly Long-Term Debt increased from Sep. 2025 (€10,639 Mil) to Dec. 2025 (€10,658 Mil) and increased from Dec. 2025 (€10,658 Mil) to Mar. 2026 (€10,738 Mil).

Viatris's annual Long-Term Debt declined from Dec. 2023 (€14,844 Mil) to Dec. 2024 (€13,407 Mil) and declined from Dec. 2024 (€13,407 Mil) to Dec. 2025 (€10,658 Mil).

Viatris  (HAM:VIA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Viatris Long-Term Debt Related Terms

Viatris Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Viatris's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Long-Term Debt Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17,449.63 17,006.35 14,844.49 13,407.15 10,658.43

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,114.19 11,090.32 10,639.44 10,658.43 10,737.68
HAM:VIA
60GF Score
Viatris Inc HAM:VIA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €10,738 Mil mean?
Viatris (HAM:VIA) has a Long-Term Debt of €10,738 Mil as of Mar. 2026.
Is Viatris' Long-Term Debt too high?
Viatris' current Long-Term Debt is €10,738 Mil. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Long-Term Debt compare to NBIX and UTHR?
Viatris' Long-Term Debt of €10,738 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Viatris's current Long-Term Debt is €10,738 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.57, compared to a current price of €14.12 — trading 47.5% above its estimated fair value. The current Long-Term Debt is €10,738 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Long-Term Debt is €10,738 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.12 is trading 47.5% above its estimated GF Value™ of €9.57. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Long-Term Debt: €10,738 Mil
  • GF Value™: €9.57 vs. price of €14.12 (47.5% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for HAM:VIA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.12
Price
€9.57
GF Value